Tempus AI posts first GAAP profit, boosts 2026 revenue forecast to $1.6B with FDA approval aiding growth

{
  "signal_id": "d5fee97e-c65e-b75d-99e7-586ff0bcc910",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-08-18T15:14:17+00:00",
  "company": {
    "name": "Tempus AI",
    "domain": "tempus.com"
  },
  "data": {
    "url": "https://pluang.com/en/news-feed/tempus-ai-putaran-data-mulai-berputar",
    "title": "Tempus AI posts first GAAP profit, boosts 2026 revenue forecast to $1.6B with FDA approval aiding growth - Pluang",
    "excerpt": "Tempus AI reported its first GAAP profit driven by growth in its data business and improved operating leverage from oncology volume and high-margin products. The company raised its 2026 revenue guidance to $1.595–$1.605 billion, a 25% increase year-over-year. FDA approval for its xT CDx test and higher pricing for xF liquid biopsy are expected to add around $400 million in revenue by 2028. The recent acquisition of Personalis aims to strengthen its position in minimal residual disease (MRD) testing. Despite a relatively high valuation, the company’s strong data assets and growth prospects support a 'Buy' rating.",
    "summary": "Tempus AI raised its 2026 revenue forecast to between $1.595 billion and $1.605 billion.",
    "planning": false,
    "image_url": "https://image-cdn.pluang.com/web/compressed/fundamentals.webp",
    "confidence": 0.9,
    "published_at": "2026-08-18T15:14:17Z",
    "article_sentence": "The company raised its 2026 revenue guidance to $1.595–$1.605 billion, a 25% increase year-over-year.",
    "amount_normalized": 1605000000000
  }
}

curl https://signals.autobound.ai/v1/signals/d5fee97e-c65e-b75d-99e7-586ff0bcc910 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"tempus.com","limit":20}'